Dimitris Voliotis
Corporate Officer/Principal bei ZENTALIS PHARMACEUTICALS, INC.
Profil
Dimitris Voliotis is a Senior Vice President-Clinical Development at Zentalis Pharmaceuticals, Inc. He was previously the Chief Development Officer at CureVac SE and Global Head-Clinical Development Oncology at Eisai, Inc. Prior to that, he was the Vice President & Head-Oncology Group at Bayer HealthCare AG.
Dr. Voliotis holds a doctorate degree from Universität zu Köln.
Aktive Positionen von Dimitris Voliotis
| Unternehmen | Position | Beginn |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.03.2020 |
Ehemalige bekannte Positionen von Dimitris Voliotis
| Unternehmen | Position | Ende |
|---|---|---|
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Corporate Officer/Principal | 01.02.2020 |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Corporate Officer/Principal | 01.01.2019 |
Bayer HealthCare AG
 Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Corporate Officer/Principal | 01.09.2014 |
Ausbildung von Dimitris Voliotis
| Universität zu Köln | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
Bayer HealthCare AG
Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Health Technology |
